Clinical trials: Recurrent Primary Peritoneal Cavity Cancer
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer
RATIONALE: A gene-modified virus may be able to kill tumor cells without damaging normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of an attenuated oncolytic measles virus therapy and oncolytic…
- Trial name
- NCT00408590
- Testing
- carcinoembryonic antigen-expressing measles virus, oncolytic measles virus encoding thyroidal sodium iodide symporter, reverse transcriptase-polymerase chain reaction
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Mayo Clinic
Ovarian Carcinoma, Fallopian Tube Cancer
Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer
This is a phase-I clinical trial to determine the feasibility and safety of Cyclophosphamide/Fludarabine Lymphodepletion and an immunomodulatory combination of Interferon-alpha Bevacizumab and Aspirin followed by adoptive…
- Conditions
- Ovarian Carcinoma, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01312376
- Testing
- OC-DC vaccine, Bevacizumab, cyclophosphamide 300 mg/m2/d for 3 days
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Cancer, Solid Tumor
MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
To determine the maximum tolerated dose (MTD) of FT538 monotherapy when administered via intraperitoneal (IP) catheter and in combination with intravenous (IV) enoblituzumab in patients with recurrent ovarian, fallopian tube, and…
- Conditions
- Cancer, Solid Tumor, Ovarian Cancer, Peritoneal Cancer
- Trial name
- NCT05708924
- Testing
- FT538, Enoblituzumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Fallopian Tube Cancer, Ovarian Cancer
Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy such as carboplatin use different ways to stop tumor cells from dividing so they stop…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00028912
- Testing
- bortezomib, carboplatin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int
This is a Phase I trial to determine the maximum tolerated dose/maximum feasible dose (MTD/MFD) of a single infusion of FATE-NK100 via intra-peritoneal catheter in women with recurrent ovarian, fallopian tube or primary…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT03213964
- Testing
- FATE-NK100, Interleukin-2
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Ovarian Cancer, Recurrent Epithelial Ovarian Cancer Which Includes Epithelial Ovarian, Fallopian Tube and/or Primary Peritoneal Cancer
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy Administered in Patients with Recurrent Epithelial Ovarian Cancer
- Trial name
- NCT06366490
- Testing
- Innocell Autologous Cellular Immunotherapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- PhotonPharma, Inc.
Fallopian Tube Cancer, Ovarian Cancer
Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have recurrent…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00004012
- Testing
- capecitabine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase I trial studies the side effects and best dose of gemcitabine hydrochloride and berzosertib when given together with carboplatin in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has…
- Conditions
- Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Ovarian Endometrioid Tumor
- Trial name
- NCT02627443
- Testing
- Berzosertib, Carboplatin, Gemcitabine Hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Peritoneal Cavity Cancer
Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00217568
- Testing
- pegfilgrastim, carboplatin, docetaxel
- Where
- 3 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Ovarian Cancer, Fallopian Tube Cancer
Panitumumab and Gemcitabine in Relapsed Ovarian Cancer
This is a study to find out if the study drug, panitumumab, when given with gemcitabine works in treating ovarian cancer and to find out what side effects occur when they are given together.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- PanGem (NCT01296035)
- Testing
- Panitumumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Women and Infants Hospital of Rhode Island
Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer
A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer) is a Phase 3 study during which patients with recurrent or persistent low-grade serous (LGS) carcinomas of the ovary, fallopian tube or primary peritoneum will…
- Conditions
- Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal Cancer
- Trial name
- NCT01849874
- Testing
- MEK162, MEK inhibitor; oral, Physician's choice chemotherapy
- Where
- 226 sites in United States, Australia and 17 more
- Volunteers
- 341 people
- Sponsor
- Pfizer
Ovarian Cancer, Fallopian Tube Cancer
Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer
This study is a phase 2, randomized, double-blind, placebo controlled, multi-center study to estimate the improvement in PFS (compared to control subjects) and evaluate the safety and tolerability of AMG 386 in combination with…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00479817
- Testing
- AMG 386, Paclitaxel
- Volunteers
- 161 people
- Sponsor
- Amgen
Brenner Tumor, Malignant Ascites
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This randomized phase II trial studies how well metformin hydrochloride and combination chemotherapy works in treating patients with stage III-IV ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Brenner Tumor, Malignant Ascites, Malignant Pleural Effusion, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT02122185
- Testing
- metformin hydrochloride, Chemotherapy
- Where
- 10 sites in United States
- Volunteers
- 111 people
- Sponsor
- University of Chicago
Ovarian Cancer, Fallopian Tube Cancer
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
Ovarian cancer is the leading cause of gynecologic cancer deaths, and the fifth most common cause of cancer deaths in women. While approximately 75% of patients with epithelial ovarian cancer will respond to first-line…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT01610206
- Testing
- Gemcitabine, pazopanib
- Where
- 8 sites in United States
- Volunteers
- 148 people
- Sponsor
- Linda R Duska
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients with recurrent…
- Trial name
- NCT00003523
- Testing
- aminocamptothecin colloidal dispersion
- Where
- 65 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Primary Peritoneal Cancer
PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer
The goal of this clinical research study is to find the highest safe dose of PS-341 that can be given with carboplatin chemotherapy as a treatment for patients with ovarian, abdominal, or fallopian tube cancer.
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT00059618
- Testing
- PS-341 (Bortezomib), Carboplatin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer, Peritoneal Cancer
A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer
This study is open to women with recurrent epithelial ovarian carcinoma or primary peritoneal cancer. Subjects will be asked to donate either a piece of their tumor or malignant effusion in order to make the first part of the…
- Trial name
- NCT00683241
- Testing
- DCVac-L
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II trial investigates the effect of irinotecan liposome and bevacizumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that shows less response to platinum therapy (platinum resistant)…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT04753216
- Testing
- Bevacizumab, Irinotecan Sucrosofate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Northwestern University
Fallopian Tube Cancer, Ovarian Cancer
Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of taurolidine in treating patients who have recurrent…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00021034
- Testing
- chemotherapy, taurolidine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
This randomized phase II trial studies the side effects and how well giving paclitaxel with or without viral therapy works in treating patients with ovarian epithelial, fallopian tube, or primary peritoneal cancer that has come…
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01199263
- Testing
- Laboratory Biomarker Analysis, Paclitaxel, Pelareorep
- Where
- 36 sites in United States
- Volunteers
- 108 people
- Sponsor
- National Cancer Institute (NCI)